Protection of dichlorvos induced oxidative stress and nigrostriatal neuronal death by chronic Coenzyme Q10 pretreatment

Toxicology and Applied Pharmacology

Volumn 256, Issue 1, 2011, Pages 73-82

  Binukumar BK, ^a   Gupta, Nidhi ^a   Bal, Amanjit ^a   Gill, Kiran Dip ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Coenzyme Q10; Dichlorvos; Nigrostriatal neurodegeneration; Parkinson's disease; ROS

Indexed keywords

ALPHA SYNUCLEIN; DICHLORVOS; DOPAMINE; UBIDECARENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; BRAIN PROTECTION; CATALEPSY; CONTROLLED STUDY; MALE; METABOLITE; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; RAT; STRIATONIGRAL DEGENERATION; TREATMENT DURATION; WISTAR ALBINO GLAXO RAT;

ANIMALS; CELL DEATH; DICHLORVOS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; UBIQUINONE;

ANIMALIA; RATTUS;

EID: 80052315301     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.07.015     Document Type: Article

References (59)

1. Akaneya Y., Takahashi M., Hatanaka H. Involvement of free radicals in MPPq neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. 1995, 193:53-56.
2. Baldi I., Cantagrel A., Lebailly P., Tison F., Dubroca B., Chrysostome V., Dartigues J.F., Brochard P. Association between Parkinson's disease and exposure to pesticides in southwestern France. Neuroepidemiology 2003, 22:305-310.
3. 10 in neurodegenerative diseases. Methods Enzymol. 2004, 382:473-487.
4. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 2004, 36(4):381-386.
5. Benecke R., Strümper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993, 116:1451-1463.
6. Beyer R.E. An analysis of the role of Coenzyme Q in free radical generation and as an antioxidant. Biochem. Cell. Biol. 1992, 70:390-403.
7. Binukumar B.K., Bal A., Kandimalla R.J., Gill K.D. Nigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, alpha synuclein aggregation, oxidative damage and behavioral changes. Mol. Brain 2010, 13;3(1):35.
8. Blair D., Dix K.M., Hunt P.F. Two year inhalation exposure of rats to dichlorvos vapour. DPR 1974, 235-050:#88033. (Tunstall Laboratory).
9. Blair D., Hoadley E.C., Hudson D.H. The distribution of dichlorvos in the tissues of mammals after its inhalation or intravenous administration. Toxicol. Appl. Pharmacol. 1975, 31:243-253.
10. 10 therapy. J. Neurol. 1999, 245:681-685.
11. Date I., Felten D.L., Felten S.Y. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 1990, 519:266-276.
12. Denka Chemie B.V. Specifications and biological activities of DDVP. DPR 1982, 235-030.
13. 10 deficiency. Neurology 2001, 57:515-518.
14. Echtay K.S., Roussel D., St-Pierre J., Jekabsons M.B., Cadenas S., Stuart J.A., Harper J.A., Roebuck S.J., Morrison A., Pickering S., Clapham J.C., Brand M.D. Superoxide activates mitochondrial uncoupling proteins. Nature 2002, 415:96-99.
15. Ellman G.L., Courtney K.D., Andres V.J.R., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
16. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 1992, 32:804-812.
17. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 23;404(6776):394-398.
18. Gaines T.B. The acute toxicity of pesticides to rats. Toxicol. Appl. Pharmacol. 1960, 2:88-99.
19. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 2002, 133:27-35.
20. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 3;290(5493):985-989.
21. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M. alpha-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157(2):401-410.
22. 10 and idebenone. J. Neurol. Sci. 1989, 90:263-271.
23. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2007, 2(1):141-151.
24. Janetzky B., Hauck S., Youdim M.B., Riederer P., Jellinger K., Pantucek F., Zöchling R., Boissl K.W., Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 1994, 169:126-128.
25. Jenner P., Schapira A.H., Marsden C.D. New insights into the cause of Parkinson's disease. Neurology 1992, 42:2241-2250.
26. Kagan V., Serbinova E., Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem. Biophys. Res. Commun. 1990, 169:851-857.
27. Kanda S., Bishop J.F., Eglitis M.A., Yang Y., Mouradian M.M. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000, 97(2):279-284.
28. Kleeman J.M. 13-Week gavage toxicity study with DDVP in rats. Amvac Chemical Corp. DPR 1988, 235-094:#74932. (Hazleton Laboratories).
29. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 1992, 32:782-788.
30. Kurlan R., Kim M.H., Gash D.M. The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann. Neurol. 1991, 29:677-679.
31. Lamb I.C. A range-finding study acute study of dichlorvos in rats. Amvac Chemical Corp. DPR 1992, 235-119:#117928. (WIL Research Lab., Inc.).
32. Lamb I.C. A subchronic (13week) neurotoxicity study of dichlorvos in rats. Amvac Chemical Corp. DPR 1993, 235-133:#126465. (WIL Research Lab., Inc.).
33. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a produce of meperidine-analog synthesis. Science 1983, 219:979-980.
34. Lovenberg W., Levine R.A., Robinson D.S., Ebert M., Williams A.C., Calne D.B. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science 1979, 204:624-626.
35. Lowary O.H., Rosebrough N.J., Farral, Randall R.J. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 1951, 193:265-275.
36. Markiewicz V.R. A 52-week chronic toxicity study on DDVP in dogs. DPR 1990, 235-106:#88784. (Hazleton Laboratories America, Inc.).
37. Mattiasson G., Friberg H., Hansson M., Elmér E., Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J. Neurochem. 2003, 87(2):532-544.
38. 10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: A31P NMR study. Neurology 1989, 39:399-403.
39. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993, 16:439-443.
40. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 1999, 15;19(14):5782-5791.
41. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-772.
42. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, London.
43. Przedborski S. Peroxiredoxin-2 links Cdk5 to neurodegeneration. Nat. Med. 2007, 13:907-909.
44. Raheja Geetu, Gill K.D. Altered cholinergic metabolism and muscarinic second messenger pathways after chronic exposure to dichlorvos in rat brain. Toxicol. Ind. Heal. 2007, 23:1-14.
45. Schapira A.H. Oxidative stress in Parkinson's disease. Neuropathol. Appl. Neurobiol. 1995, 21:3-9.
46. 10 reductase (complex I). Deficiency in Parkinson's disease. J. Neurochem. 1990, 55:2142-2145.
47. 10 in neurodegenerative diseases. Curr. Med. Chem. 2002, 10:1917-1921.
48. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 1997, 42:261-264.
49. Singer T.P., Castagnoli N., Ramsay R.R., Trevor A.J. Biochemical events in the development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 1987, 49:1-8.
50. 10 in aged rat skeletal muscle. Biochem. Mol. Biol. Int. 1995, 37:1110-1120.
51. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 2000, 1;9(18):2683-2689.
52. The Hine Lab. 90-Day chronic toxicity studies of Vapona insecticide for dogs. DPR 1962, 235-070:#35421. Shell Chemical Company.
53. Thorpe E., Wilson A.B., Dix K.M., Blair D.B. Toxicity studies with dichlorvos: teratogenic studies in rats and rabbits given dichlorvos by inhalation. DPR 1971, 235-072:#35428. (Tunstall Laboratory).
54. 10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic. Biol. Med. 1999, 27:1027-1032.
55. Tyl R.W. Draft results of DDVP range-finding two-generation study. DPR 1990, 235-105:#88543. (Research Triangle Institute), Amvac Chemical Company.
56. Verma S.K., Raheja G., Gill K.D. Role of muscarinic signal transduction and CREB phosphorylation in dichlorvos-induced memory deficits in rats: an acetylcholine independent mechanism. Toxicology 2009, 27;256(3):175-182.
57. 10 in human blood plasma. Int. J. Vitam. Nutr. Res. 1994, 64:311-315.
58. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:6145-6150.
59. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural. Transm. 1992, 4:27-34.